CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received an average recommendation of “Hold” from the twenty-one research firms that are currently covering the stock, MarketBeat.com reports ...

Researchers have developed a novel method using CRISPR to study transcription factors affecting blood cell development. The ...

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...

RAPID-CRISPR test quickly and accurately diagnoses acute promyelocytic leukemia, a rare and aggressive blood cancer, with ...

Climate change is rapidly altering the agricultural landscape, leaving farmers scrambling to adjust. As temperatures rise, ...

CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and ...

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $32.65, marking a -0.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 5.98%.

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) ...